Full Press Release Details
RadNet Reports Record 2010 Fourth Quarter Results and Releases 2011 Financial Guidance
LOS ANGELES, California., March 8, 2011 - RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 201 owned and/or operated outpatient imaging centers (inclusive of 19 facilities held in Joint Ventures), today reported financial results for its fourth quarter and full year ended December 31, 2010.
Fourth Quarter Report:
For the fourth quarter of 2010, RadNet reported Revenue, Adjusted EBITDA(1) and Net Income of $145.3 million, $30.2 million and $3.3 million, respectively. Revenue increased $13.5 million (or 10.2%), Adjusted EBITDA(1) increased $3.2 million (or 11.8%) and Net Income increased $2.7 million (or 418.1%) over the fourth quarter of 2009. On a sequential year-over-year basis, compared with the first, second and third quarters of 2010, Revenue increased $21.1 million (or 17.0%), $6.4 million (or 4.6%) and $5.2 million (or 3.7%), respectively. On a sequential basis, compared with the first, second and third quarters of 2010, Adjusted EBITDA(1) increased $9.7 million (or 47.1%), $2.8 million (or 10.0%) and $2.1 million (or 7.6%), respectively.
Net Income for the fourth quarter was $0.09 per share, compared with a Net Income of $0.02 per share in the fourth quarter of 2009 (based upon a weighted average number of fully diluted shares outstanding of 37.8 million and 37.4 million for these periods in 2010 and 2009, respectively). Excluding non-cash gains from the mark-to-market of our interest rate swaps of $1.8 million, a $306,000 non-cash charge to interest expense related to the amortization of accumulated unrealized losses on interest rate swaps, losses from the disposal of equipment of $530,000 and non-cash stock compensation of $898,000, RadNet would have reported Net Income of $3.2 million, or $0.08 per fully diluted share, for the fourth quarter of 2010 compared with a Net Income of $1.5 million, or $0.04 per share, for the fourth quarter of 2009 excluding those same non-cash losses and expenses.
Also affecting Net Income in the fourth quarter of 2010 were certain other non-cash expenses and non-recurring items, including $107,000 of severance paid in connection with employee reductions related to cost savings initiatives and $723,000 of non-cash Deferred Financing Expense related to the amortization of financing fees paid as part of our new credit facilities and senior unsecured notes.
For the fourth quarter of 2010, as compared with the prior year's fourth quarter, MRI volume increased 16.4%, CT volume increased 4.6% and PET/CT volume decreased 7.4%. Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 8.6% over the prior year's third quarter. On a same-center basis, including only those centers which were part of RadNet for both the fourth quarters of 2010 and 2009, MRI volume increased 7.9%, CT volume decreased 6.7% and PET/CT volume decreased 10.3%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 0.5% over the prior year's same quarter.
Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented "We are pleased to have ended 2010 with strong fourth quarter results. In the fourth quarter, we obtained record Revenues, Adjusted EBITDA(1) and Net Income. Our results illustrate the strength of our operating model. Relative size and operating efficiency remain increasingly important in our industry, particularly in what is a very challenged economic and reimbursement climate. While we observe the struggles of many of our competitors, our multi-modality approach and geographic clustering operating model has made RadNet a resilient and stable operating force in our industry. "
"We are particularly excited about the future opportunities for RadNet. In the last few months, we have taken important strategic steps towards broadening the scope of our Company. Our entrances into the radiology software and teleradiology businesses have already begun to widen the scope of opportunities we are pursuing. In particular, we are excited about the potential for new partnerships with major hospital and health systems, where we are now able to offer a multi-disciplined approach of diversified radiology solutions. Furthermore, after experiencing an operating environment in 2010 where the general utilization of healthcare services was depressed, we have begun to see stabilization of procedural volumes at our centers. This provides us encouragement as we move further into 2011."
For full year 2010, the Company reported Revenue, Adjusted EBITDA(1) and Net Loss of $548.5 million, $106.2 million and $(12.9) million, respectively. Revenue increased $24.2 million (or 4.6%), Adjusted EBITDA(1) increased $0.3 million (or 0.3%) and Net Loss increased $10.6 million, respectively, from full year 2009 results.
The increase in Net Loss in 2010 was primarily the result of a $9.9 million Loss on Debt Extinguishment related to our debt refinancing transaction we completed in April of 2010. Excluding the Loss on Debt Extinguishment, Net Loss for 2010 would have been $(0.08) per share, compared to a Net Loss of $(0.06) per share in 2009 (based upon a weighted average number of basic shares outstanding of 36.9 million and 36.0 million in 2010 and 2009, respectively). Affecting Net Loss in 2010 were certain non-cash expenses and non-recurring items including: $3.7 million of non-cash employee stock compensation expense resulting from the vesting of certain options and warrants; $2.8 million of non-cash Deferred Financing Expense related to the amortization of financing fees paid as part of our existing credit facilities; $0.8 million of severance paid in connection with the headcount reductions related to cost savings initiatives from previously announced acquisitions; $1.1 million loss on the disposal of certain capital equipment; and $917,000 non-cash charge to interest expense related to the amortization of accumulated unrealized losses on interest rate swaps related to the Company's credit facilities.
For the year ended December 31, 2010, as compared to 2009, MRI volume increased 7.9%, CT volume decreased 0.6% and PET/CT volume decreased 5.1%. Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 4.4% for the twelve months of 2010 over 2009.
2011 Fiscal Year Guidance
For its 2011 fiscal year, RadNet announces its guidance ranges as follows:
| Revenue | $575 million - $605 million |
| Adjusted EBITDA (1) | $110 million - $120 million |
| Capital Expenditures (a) | $35 million - $40 million |
| Cash Interest Expense | $45 million - $49 million |
| Free Cash Flow Generation (b) | $25 million - $35 million |
"Our guidance reflects our belief that we will continue to grow both our revenue and EBITDA in 2011," said Dr. Berger. "Although we see a stabilization of procedural volumes and have reason to believe we could experience some volume increases in 2011, the midpoint of our guidance assumes flat same center revenue as compared with 2010. We are anticipating Revenue and Adjusted EBITDA(1) contribution in 2011 from the several acquisitions we completed at various times during 2010, as well as the recently announced acquisitions of Imaging On Call and Diagnostic Health businesses in 2011. We are also anticipating that we will achieve certain cost reductions necessary to substantially mitigate reimbursement cuts to which we are subject in 2011," added Dr. Berger.
Actual 2010 Results vs. 2010 Guidance:
The following compares the Company's actual 2010 performance with previously announced guidance levels.
| Updated Guidance Range | Actual Results | ||
| Revenue | $540 million - $560 million | $548.5 million | |
| Adjusted EBITDA (1) | $107 million - $111 million | $106.2 million | |
| Capital Expenditures (a) | $34 million - $38 million | $39.6 million | |
| Cash Interest Expense | $42 million - $47 million | $40.4 million | |
| Free Cash Flow Generation (b) | $25 million - $35 million | $26.2 million |
Dr. Berger commented, "Despite a more challenged economy and operating environment than we could have predicted when we set our original guidance for 2010, our Revenue and Free Cash Flow Generation fell in-line with our guidance levels, while we benefited from a lower Cash Interest Expense than we had anticipated. Our Adjusted EBITDA(1) performance was below our range by about $800,000, despite a larger than anticipated negative effect of severe weather in our first quarter and lower than expected utilization of healthcare services in 2010 which impacted our same center volumes. We were pleased that after the first quarter, we showed substantial sequential improvement in our Adjusted EBITDA(1) and operating margins. We attribute much of this improvement throughout 2010 to our ability to closely manage and reduce operating costs, drive efficiencies from acquired entities and drive increased procedural volumes as the year progressed."
Conference Call for Today
Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call today, at 10:30 a.m. Eastern Standard Time. During the call management, will discuss the Company's 2010 fourth quarter and year-end results.
Conference Call Details:
Date: Tuesday, March 8, 2010
Time: 10:30 a.m. EST
Dial In-Number: 888-797-2983
International Dial-In Number: 913-312-0409
There will also be simultaneous and archived webcasts available at http://viavid.net/dce.aspx?sid=000081C2 or http://www.radnet.com under the "Investors" menu section and "News Releases" sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 877-870-5176 from the U.S., or 858-384-5517 for international callers, and using the passcode 6797865.
Regulation G: GAAP and Non-GAAP Financial Information
This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.
RadNet, Inc. is a national market leader providing high-quality, cost-effective diagnostic imaging services through a network of 201 owned and/or operated outpatient imaging centers (inclusive of 19 facilities held in Joint Ventures). RadNet's core markets include California, Maryland, Delaware, New Jersey and New York. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 4,500 employees. For more information, visit http://www.radnet.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning successfully integrating acquired operations, successfully achieving 2011 financial guidance, achieving cost savings, successfully developing and integrating new lines of business, continuing to grow its business by generating patient referrals and contracts with radiology practices, and receiving third-party reimbursement for diagnostic imaging services, are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause the Company's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect RadNet's business and its financial results are detailed in its most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. RadNet undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
Mark Stolper, 310-445-2800
Executive Vice President and Chief Financial Officer
RADNET, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS EXCEPT SHARE DATA)
| December 31, | ||||||||
| 2010 | 2009 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 627 | $ | 10,094 | ||||
| Accounts receivable, net | 96,094 | 87,825 | ||||||
| Prepaid expenses and other current assets | 14,304 | 9,990 | ||||||
| Total current assets | 111,025 | 107,909 | ||||||
| PROPERTY AND EQUIPMENT, NET | 194,230 | 182,571 | ||||||
| OTHER ASSETS | ||||||||
| Goodwill | 143,353 | 106,502 | ||||||
| Other intangible assets | 57,348 | 54,313 | ||||||
| Deferred financing costs, net | 15,486 | 8,229 | ||||||
| Investment in joint ventures | 15,444 | 18,741 | ||||||
| Deposits and other | 2,628 | 2,406 | ||||||
| Total assets | $ | 539,514 | $ | 480,671 | ||||
| LIABILITIES AND EQUITY DEFICIT | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable and accrued expenses | $ | 82,619 | $ | 69,641 | ||||
| Due to affiliates | 2,975 | 7,456 | ||||||
| Deferred revenue | 1,568 | - | ||||||
| Current portion of notes payable | 8,218 | 6,927 | ||||||
| Current portion of deferred rent | 745 | 560 | ||||||
| Current portion of obligations under capital leases | 9,139 | 14,121 | ||||||
| Total current liabilities | 105,264 | 98,705 | # | |||||
| LONG-TERM LIABILITIES | ||||||||
| Deferred rent, net of current portion | 10,379 | 8,920 | ||||||
| Deferred taxes | 277 | 277 | ||||||
| Notes payable, net of current portion | 481,578 | 416,699 | ||||||
| Obligations under capital lease, net of current portion | 5,639 | 13,568 | ||||||
| Other non-current liabilities | 18,850 | 17,263 | ||||||
| Total liabilities | 621,987 | 555,432 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| EQUITY DEFICIT | ||||||||
| Common stock - $.0001 par value, 200,000,000 shares authorized; 37,223,475 and 36,259,279 shares issued and outstanding at December 31, 2010 and 2009, respectively | 4 | 4 | ||||||
| Paid-in-capital | 162,444 | 156,758 | ||||||
| Accumulated other comprehensive loss | (2,137 | ) | (1,588 | ) | ||||
| Accumulated deficit | (242,841 | ) | (229,989 | ) | ||||
| Total Radnet, Inc.'s equity deficit | (82,530 | ) | (74,815 | ) | ||||
| Noncontrolling interests | 57 | 54 | ||||||
| Total equity deficit | (82,473 | ) | (74,761 | ) | ||||
| Total liabilities and equity deficit | $ | 539,514 | $ | 480,671 |
The accompanying notes are an integral part of these financial statements.
RADNET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS EXCEPT SHARE DATA)
| Years Ended December 31, | ||||||||||||
| 2010 | 2009 | 2008 | ||||||||||
| NET REVENUE | $ | 548,537 | $ | 524,368 | $ | 498,815 | ||||||
| OPERATING EXPENSES | ||||||||||||
| Cost of operations | 420,973 | 397,753 | 384,297 | |||||||||
| Depreciation and amortization | 53,997 | 53,800 | 53,548 | |||||||||
| Provision for bad debts | 33,158 | 32,704 | 30,832 | |||||||||
| Loss on sale of equipment | 1,136 | 523 | 516 | |||||||||
| Severance costs | 838 | 731 | 335 | |||||||||
| Total operating expenses | 510,102 | 485,511 | 469,528 | |||||||||
| INCOME FROM OPERATIONS | 38,435 | 38,857 | 29,287 | |||||||||
| OTHER EXPENSES (INCOME) | ||||||||||||
| Interest expense | 48,398 | 50,016 | 51,811 | |||||||||
| Gain on bargain purchase | - | (1,387 | ) | - | ||||||||
| Loss on extinguishment of debt | 9,871 | - | - | |||||||||
| Other expenses (income) | 505 | 416 | (151 | ) | ||||||||
| Total other expenses | 58,774 | 49,045 | 51,660 | |||||||||
| LOSS BEFORE INCOME TAXES AND EQUITY | ||||||||||||
| IN EARNINGS OF JOINT VENTURES | (20,339 | ) | (10,188 | ) | (22,373 | ) | ||||||
| Provision for income taxes | (576 | ) | (443 | ) | (151 | ) | ||||||
| Equity in earnings of joint ventures | 8,230 | 8,456 | 9,791 | |||||||||
| NET LOSS | (12,685 | ) | (2,175 | ) | (12,733 | ) | ||||||
| Net income attributable to noncontrolling interests | 167 | 92 | 103 | |||||||||
| NET LOSS ATTRIBUTABLE TO RADNET, INC. | ||||||||||||
| COMMON STOCKHOLDERS | $ | (12,852 | ) | $ | (2,267 | ) | $ | (12,836 | ) | |||
| BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE | ||||||||||||
| TO RADNET, INC. COMMON STOCKHOLDERS | $ | (0.35 | ) | $ | (0.06 | ) | $ | (0.36 | ) | |||
| WEIGHTED AVERAGE SHARES OUTSTANDING | ||||||||||||
| Basic and Diluted | 36,853,477 | 36,047,033 | 35,721,028 |
The accompanying notes are an integral part of these financial statements.
RADNET, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Years Ended December 31, | ||||||||||||
| 2010 | 2009 | 2008 | ||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||||||
| Net loss | $ | (12,685 | ) | $ | (2,175 | ) | $ | (12,733 | ) | |||
| Adjustments to reconcile net loss | ||||||||||||
| to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | 53,997 | 53,800 | 53,548 | |||||||||
| Provision for bad debts | 33,158 | 32,704 | 30,832 | |||||||||
| Equity in earnings of joint ventures | (8,230 | ) | (8,456 | ) | (9,791 | ) | ||||||
| Distributions from joint ventures | 10,917 | 7,667 | 7,982 | |||||||||
| Deferred rent amortization | 1,848 | 1,094 | 3,514 | |||||||||
| Amortization of deferred financing cost | 2,797 | 2,678 | 2,567 | |||||||||
| Amortization of bond discount | 164 | - | - | |||||||||
| Net loss on disposal of assets | 1,136 | 523 | 516 | |||||||||
| Loss on extinguishment of debt | 9,871 | - | - | |||||||||
| Gain on bargain purchase | - | (1,387 | ) | - | ||||||||
| Gain on extinguishment of debt | - | - | (47 | ) | ||||||||
| Amortization of cash flow hedge | 917 | 6,119 | - | |||||||||
| Stock-based compensation | 3,718 | 3,607 | 2,902 | |||||||||
| Changes in operating assets and liabilities, net of assets | ||||||||||||
| acquired and liabilities assumed in purchase transactions: | ||||||||||||
| Accounts receivable | (35,985 | ) | (24,432 | ) | (36,297 | ) | ||||||
| Other current assets | (3,226 | ) | 4,206 | (1,515 | ) | |||||||
| Other assets | 24 | 51 | 684 | |||||||||
| Deferred revenue | 207 | |||||||||||
| Accounts payable and accrued expenses | 8,256 | 619 | 3,270 | |||||||||
| Net cash provided by operating activities | 66,884 | 76,618 | 45,432 | |||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||||||
| Purchase of imaging facilities | (61,774 | ) | (6,085 | ) | (28,859 | ) | ||||||
| Proceeds from sale of imaging facilities | - | 650 | - | |||||||||
| Purchase of property and equipment | (40,293 | ) | (30,752 | ) | (29,199 | ) | ||||||
| Proceeds from sale of equipment | 685 | 219 | 2,961 | |||||||||
| Purchase of equity interest in joint ventures | - | (315 | ) | (938 | ) | |||||||
| Net cash used in investing activities | (101,382 | ) | (36,283 | ) | (56,035 | ) | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||||||
| Principal payments on notes and leases payable | (21,463 | ) | (23,660 | ) | (19,112 | ) | ||||||
| Proceeds from borrowings on notes payable | - | - | 35,000 | |||||||||
| Proceeds from borrowings upon refinancing | 482,360 | - | 1,212 | |||||||||
| Repayment of bebt | (412,000 | ) | ||||||||||
| Deferred financing costs | (17,613 | ) | - | (4,277 | ) | |||||||
| Net payments on line of credit | - | (1,742 | ) | (2,480 | ) | |||||||
| Payments to counterparties of interest rate swaps, net of amounts received | (6,382 | ) | (4,739 | ) | - | |||||||
| Distributions to noncontrolling interests | (131 | ) | (116 | ) | (231 | ) | ||||||
| Proceeds from issuance of common stock upon exercise of options/warrants | 271 | 16 | 473 | |||||||||
| Net cash provided by (used in) financing activities | 25,042 | (30,241 | ) | 10,585 | ||||||||
| EFFECT OF EXCHANGE RATE CHANGES ON CASH | (11 | ) | - | - | ||||||||
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | (9,467 | ) | 10,094 | (18 | ) | |||||||
| CASH AND CASH EQUIVALENTS, beginning of period | 10,094 | - | 18 | |||||||||
| CASH AND CASH EQUIVALENTS, end of period | $ | 627 | $ | 10,094 | $ | - | ||||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||||||||||||
| Cash paid during the period for interest | $ | 40,352 | $ | 40,092 | $ | 49,236 | ||||||
| Cash paid during the period for income taxes | $ | 659 | $ | 348 | $ | 389 |
The accompanying notes are an integral part of these financial statements.
RECONCILIATION OF GAAP NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA(1)
| Three Months Ended | ||||||||
| December 31, | ||||||||
| 2010 | 2009 | |||||||
| Net Income Attributable to RadNet, Inc. Common Shareholders | $ | 3,300 | $ | 637 | ||||
| Plus Provision for Income Taxes | 53 | 162 | ||||||
| Plus Other Expenses (Income) | (1,466 | ) | - | |||||
| Plus Interest Expense | 12,921 | 11,478 | ||||||
| Plus Severence Costs | 107 | 88 | ||||||
| Plus Loss on Sale of Equipment | 530 | 148 | ||||||
| Plus Depreciation and Amortization | 13,844 | 13,821 | ||||||
| Plus Non Cash Employee Stock Compensation | 898 | 670 | ||||||
| Adjusted EBITDA (1) | $ | 30,187 | $ | 27,004 |
| Fiscal Year Ended | ||||||||
| December 31, | ||||||||
| 2010 | 2009 | |||||||
| Net Loss Attributable to RadNet, Inc. Common Shareholders | $ | (12,852 | ) | $ | (2,267 | ) | ||
| Plus Provision for Income Taxes | 576 | 443 | ||||||
| Plus Other Expenses (Income) | 505 | 416 | ||||||
| Plus Interest Expense | 48,398 | 50,016 | ||||||
| Plus Severence Costs | 838 | 731 | ||||||
| Plus Loss on Sale of Equipment | 1,136 | 523 | ||||||
| Plus Depreciation and Amortization | 53,997 | 53,800 | ||||||
| Plus Non Cash Employee Stock Compensation | 3,718 | 3,607 | ||||||
| Plus Loss on Extinguishment of Debt | 9,871 | - | ||||||
| Less Gain on Bargain Purchase | - | (1,387 | ) | |||||
| Adjusted EBITDA (1) | $ | 106,187 | $ | 105,882 |
| RADNET PAYMENTS BY PAYORS * | ||||||||||||||||
| Three Months Ended | ||||||||||||||||
| December 31, | Years Ended December 31, | |||||||||||||||
| 2010 | 2010 | 2009 | 2008 | |||||||||||||
| Commercial Insurance | 55.8 | % | 55.7 | % | 55.8 | % | 56.6 | % | ||||||||
| Medicare | 19.3 | % | 19.3 | % | 20.0 | % | 19.6 | % | ||||||||
| Capitation | 15.2 | % | 15.3 | % | 15.4 | % | 15.0 | % | ||||||||
| Workers Compensation/Personal Injury | 3.9 | % | 4.1 | % | 3.5 | % | 3.7 | % | ||||||||
| Medicaid | 3.3 | % | 3.2 | % | 3.2 | % | 3.1 | % | ||||||||
| Other | 2.6 | % | 2.4 | % | 2.1 | % | 2.0 | % | ||||||||
| 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % |
| RADNET PAYMENTS BY MODALITY * | ||||||||||||||||
| Three Months Ended | ||||||||||||||||
| December 31, | Years Ended December 31, | |||||||||||||||
| 2010 | 2010 | 2009 | 2008 | |||||||||||||
| MRI | 34.2 | % | 34.3 | % | 34.1 | % | 34.2 | % | ||||||||
| CT | 17.2 | % | 17.5 | % | 19.1 | % | 19.0 | % | ||||||||
| PET/CT | 5.9 | % | 6.1 | % | 6.0 | % | 6.2 | % | ||||||||
| X-ray | 10.3 | % | 10.1 | % | 9.8 | % | 10.8 | % | ||||||||
| Ultrasound | 11.3 | % | 11.0 | % | 10.3 | % | 10.2 | % | ||||||||
| Mammography | 16.1 | % | 16.0 | % | 16.0 | % | 14.9 | % | ||||||||
| Nuclear Medicine | 1.8 | % | 1.7 | % | 1.7 | % | 1.6 | % | ||||||||
| Other | 3.3 | % | 3.2 | % | 3.0 | % | 3.1 | % | ||||||||
| 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % |
| RADNET AVERAGE PAYMENTS BY MODALITY * | ||||||||||||||||
| Three Months Ended | ||||||||||||||||
| December 31, | Years Ended December 31, | |||||||||||||||
| 2010 | 2010 | 2009 | 2008 | |||||||||||||
| MRI | $ | 501 | $ | 501 | $ | 503 | $ | 505 | ||||||||
| CT | 305 | 306 | 308 | 310 | ||||||||||||
| PET/CT | 1,492 | 1,494 | 1,493 | 1,494 | ||||||||||||
| X-ray | 39 | 40 | 38 | 37 | ||||||||||||
| Ultrasound | 106 | 107 | 108 | 107 | ||||||||||||
| Mammography | 136 | 135 | 135 | 134 | ||||||||||||
| Nuclear Medicine | 322 | 322 | 323 | 327 | ||||||||||||
| Other | $ | 126 | $ | 126 | $ | 127 | $ | 129 |
* Based upon global payments received from consolidated Imaging Centers from that year's dates of service.
Excludes payments from hospital contracts, Breastlink, Center Management Fees and other miscellaneous operating activities.
(1) The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and excludes losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments, bargain purchase gains and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period.
Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.
(2) As noted above, the Company defines Free Cash Flow as Adjusted EBITDA less total Capital Expenditures (whether completed with cash or financed) and Cash Interest paid. Free Cash Flow is a non-GAAP financial measure. The Company uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other companies.
Free Cash Flow should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.